Cidara Therapeutics is a San Diego-based biopharmaceutical company that is dedicated to developing targeted immunotherapies to improve the standard of care for patients with serious diseases. Their innovative Cloudbreak platform creates single molecule cocktails that combine small molecules and peptides with a human antibody fragment Fc, resulting in drug-Fc conjugates called DFC immunotherapies. These therapies are designed to inhibit specific disease targets while engaging the immune system, with the ultimate goal of saving lives.
With a focus on transformative outcomes, Cidara Therapeutics is committed to advancing their pipeline of immunotherapies, including their lead candidate rezafungin. Through partnerships, publications, and a dedicated team, the company aims to make a significant impact in the field of targeted immunotherapy and contribute to the advancement of patient care.
Generated from the website